NDAORALTABLET
Approved
May 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZESTRIL (lisinopril) by Lavipharm is angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension, heart failure, diabetes mellitus type 2 and 1 more indications. First approved in 1988.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZESTRIL (lisinopril) is an oral ACE inhibitor approved in 1988 that reduces blood pressure and improves survival in heart failure and post-MI patients by suppressing the renin-angiotensin-aldosterone system. It works by inhibiting angiotensin-converting enzyme, preventing conversion of angiotensin I to the potent vasoconstrictor angiotensin II.
$4MPart D
LOE ApproachingDeclining
Product is approaching loss of exclusivity with modest Medicare spending; brand team focus is likely on managed decline and generic transition support.
Mechanism of Action
angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of…
Indications (4)
Worked on ZESTRIL at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.